IND-Enabling Studies: What They Include & How to Plan
IND-enabling studies are nonclinical studies conducted to characterize a drug candidate's pharmacology, disposition, and safety before clinical development. The specific program depends on the therapeutic modality, intended clinical use, route of administration, existing data, and applicable regulatory expectations rather than a single universal set of studies. IND-enabling studies are better understood as coordinated programs, not one individual test. These comprehensive programs commonly integrate drug metabolism and pharmacokinetics, toxicology, and bioanalytical work. Because study requirements and sequencing depend heavily on the test article and intended clinical program, earlier nonclinical findings should inform definitive study design, and multidisciplinary planning is essential.
What Is an IND-Enabling Study?
An IND-enabling study is a nonclinical study designed to generate pharmacology, pharmacokinetic, safety, or other data needed to support progression toward clinical development. The complete IND-enabling program typically includes multiple studies selected according to the drug candidate, clinical plan, existing evidence, and applicable regulatory expectations.
During nonclinical development, IND-enabling studies help generate the pharmacology, exposure, and safety information needed to support progression toward initial clinical studies. The studies selected depend on the therapeutic modality, intended clinical plan, existing evidence, and applicable regulatory expectations. An IND-enabling program may include general toxicology, safety pharmacology, genetic toxicology, DMPK, and supporting bioanalysis, among other evaluations as appropriate.
Program design is always influenced by the intended clinical indication, route of administration, dose, treatment duration, therapeutic modality, and existing data.
What Studies Are Included in an IND-Enabling Program?
Study selection is highly program-specific and generally spans three major, interconnected technical disciplines.
|
Area |
Questions It Can Help Answer |
Potential Study Components |
|
DMPK |
How is the test article absorbed, distributed, metabolized, and eliminated? |
In vitro ADME/DMPK, PK, mass balance, metabolite characterization |
|
Toxicology |
What safety findings and exposure relationships need to be characterized before clinical development? |
General toxicology, safety pharmacology, genetic toxicology, other studies as applicable |
|
Bioanalysis |
How will exposure and relevant biological measurements be quantified? |
PK/TK bioanalysis, immunogenicity where applicable, method development and validation |
DMPK and Pharmacokinetics
Earlier in vitro DMPK evaluations characterize fundamental properties such as metabolic stability, permeability, protein binding, and potential drug interaction liabilities where applicable. Subsequent in vivo pharmacokinetic studies measure systemic exposure and disposition over time. DMPK findings help guide chemical structure optimization, inform dose selection, and dictate toxicology study design. Metabolite characterization may also be incorporated where relevant to ensure that downstream transformation products are fully understood.
Toxicology
Preclinical toxicology assessments are critical to evaluating potential adverse effects and exposure relationships. General toxicology studies evaluate repeat-dose toxicity, while safety pharmacology assessments examine vital organ systems such as the cardiovascular, pulmonary, and central nervous systems. Depending on the modality, genetic toxicology and local tolerance or specialized evaluations may also be included.
Study designs are heavily influenced by the route of administration, intended clinical duration, structural modality, and prior pharmacological findings. Toxicokinetic data gathered concurrently helps interpret systemic exposure alongside observed safety findings.
Bioanalysis
Preclinical bioanalysis flows through the entire IND-enabling process by quantifying the test article and relevant analytes in complex biological matrices like plasma and blood. This discipline supports pharmacokinetic and toxicokinetic evaluations, as well as immunogenicity assessments where applicable. Rigorous method development, qualification, and validation help establish appropriate analytical sensitivity and specificity, and assess analyte stability under relevant sample handling and storage conditions. Because bioanalytical data underpin safety and disposition conclusions, analytical strategies must be coordinated closely with DMPK and toxicology study designs from the outset.
WuXi AppTec Biology and Testing’s bioanalytical lab has been developing methods and analyzing bioanalytical samples since 2004 to support global preclinical studies. Developing these validated methods according to the regulators’ guidance is an in-depth process in and of itself.
How Do IND-Enabling Studies Work Together?
IND-enabling studies are most useful when DMPK, toxicology, and bioanalysis are planned as an integrated program. DMPK data can inform exposure and dose selection, bioanalysis quantifies relevant concentrations during studies, and toxicology findings are interpreted alongside exposure and other nonclinical evidence.
Moving beyond isolated discipline-by-discipline descriptions, an effective IND-enabling program functions as an interconnected, cohesive whole where distinct functional areas directly drive and influence one another:
- DMPK informs exposure and dose selection: Baseline absorption, distribution, metabolism, and excretion data help project human pharmacokinetics and establish appropriate boundaries for safety margins.
- Bioanalysis measures exposure during studies: Appropriate bioanalytical assays quantify test article and relevant analytes across biological matrices, providing the exposure data needed to support pharmacokinetic and toxicokinetic evaluations.
- Toxicology evaluates safety findings in the context of exposure: Observed toxicological endpoints are never reviewed in a vacuum; they rely entirely on systemic exposure measurements to differentiate between target-mediated adverse effects and high-dose saturation phenomena.
- Earlier findings refine subsequent definitive studies: Data emerging from exploratory assessments iteratively shape the design, scheduling, and endpoint selection of subsequent definitive trials.
Several core operational dynamics govern this integrated approach:
- Data from one discipline frequently alter study design in another; for instance, unexpected clearance patterns discovered during DMPK evaluations can prompt immediate adjustments to bioanalytical sampling intervals or toxicology dose tiers.
- Comprehensive exposure information is essential to properly contextualize toxicology findings, ensuring accurate interpretation of safety margins.
- Analytical methods should be appropriately developed and qualified or validated, as required, to handle the specific samples and endpoints of upcoming studies before dosing begins.
- Unexpected scientific findings often surface during testing, creating requirements for additional characterization or follow-up work that must be accommodated within the timeline.
- Coordinated multi-disciplinary planning significantly reduces avoidable operational gaps and scheduling bottlenecks between sequential study phases.
When Should IND-Enabling Studies Begin?
Drug developers should begin planning an IND-enabling study program when enough information exists to define the core parameters of the development path. Planning does not necessarily mean immediately initiating definitive studies; rather, it requires establishing a clear framework based on:
- Intended clinical indication and development objective: Establishing the targeted therapeutic context ensures that nonclinical safety and pharmacology endpoints align with future clinical trials.
- Therapeutic modality and test article characteristics: Defining whether the candidate is a small molecule, biologic, or specialized therapeutic dictates structural and analytical requirements.
- Intended route of administration: Knowing how the drug will be delivered guides local tolerance, pharmacokinetic, and toxicology study designs.
- Preliminary pharmacology: Initial pharmacodynamic data confirm that the candidate exhibits biological activity that justifies further development.
- Existing DMPK/PK information: Baseline absorption, distribution, metabolism, and excretion insights help map out systemic exposure expectations.
- Preliminary safety or tolerability information: Initial toxicity signals or maximum tolerated dose estimates help structure subsequent repeat-dose evaluations.
- Formulation and dose considerations: Understanding how the test article is formulated and delivered prevents technical bottlenecks during dosing phases.
- Expected clinical dosing duration where relevant: Anticipated treatment schedules dictate the necessary duration of nonclinical repeat-dose toxicology studies.
- Major analytical requirements: Identifying specialized assay needs early ensures that bioanalytical methods can be developed and validated prior to definitive testing.
- Applicable regulatory questions: Outlining specific agency expectations allows teams to address potential compliance or design requirements before trials begin.
Early preparation allows teams to map out necessary timelines without rushing experimental execution, which is vital given the intricate nature of nonclinical evaluation frameworks.
How Do You Plan an IND-Enabling Study Program?
1. Define the Clinical and Regulatory Objective
Establish what the nonclinical program ultimately needs to support by outlining the intended indication, route of administration, expected clinical dosing, treatment duration, target patient population, and applicable regulatory pathways.
2. Identify Existing Data and Remaining Questions
Review available pharmacology, DMPK, preliminary toxicology, formulation, bioanalytical methods, and metabolite data to pinpoint which scientific uncertainties must be resolved before advancing to definitive phases.
3. Determine Which Studies Need to Be Exploratory vs. Definitive
Use fit-for-purpose preliminary studies to answer unresolved questions before parameters are locked into controlled designs. Not every study within an IND-enabling program must be conducted under Good Laboratory Practice conditions; GLP applicability depends on the study type, intended regulatory use, and applicable requirements.
4. Establish Study Dependencies and Sequence
Map out operational sequencing to prevent delays caused by unready materials, methods, or inputs. Consider dose-selection dependencies, formulation readiness, bioanalytical method validation status, test article availability, and scheduling coordination across facilities.
5. Build Time for Data Interpretation and Follow-Up
Avoid planning solely around active study execution. Incorporate dedicated time for data analysis, final reporting, cross-study interpretation, potential regulatory interactions, and any follow-up characterization prompted by unexpected findings.
Planning an IND-enabling study program? Explore WuXi AppTec's integrated DMPK, toxicology, and bioanalytical capabilities to identify study dependencies and coordinate nonclinical development activities.
What Role Does Regulatory Planning Play in IND-Enabling Studies?
Identifying applicable guidance and regulatory expectations early ensures that nonclinical data packages align with agency standards. Because the intended clinical plan dictates study design, developers benefit from defining unresolved regulatory questions prior to initiating definitive work. Documenting the scientific rationale behind the overall nonclinical strategy helps clarify expectations, allowing study plans to evolve smoothly in response to emerging data or regulatory feedback.
Choosing a Laboratory Testing Partner for IND-Enabling Studies
Evaluating prospective testing collaborators involves examining core operational and scientific competencies across several dimensions:
- Breadth of DMPK, toxicology, and bioanalytical capabilities
- Experience coordinating multidisciplinary nonclinical programs
- Established GLP and non-GLP testing capabilities
- Regulatory and filing support expertise
- Advanced method development and validation infrastructure
- Seamless integration of exposure and safety datasets
- Program management, communication, and scheduling capacity
Drug developers may also evaluate whether a laboratory testing partner can coordinate DMPK, bioanalysis, and toxicology activities across an integrated nonclinical program. WuXi AppTec provides capabilities across these disciplines, enabling teams to coordinate study planning, data generation, and cross-disciplinary communication within a broader IND-enabling strategy.
Frequently Asked Questions About IND-Enabling Studies
What is an IND-enabling study?
An IND-enabling study is a nonclinical investigation conducted to generate pharmacology, pharmacokinetic, or safety data required to support an Investigational New Drug application, with complete programs typically comprising multiple integrated studies.
What studies are included in an IND-enabling program?
An IND-enabling program may include a tailored combination of DMPK evaluations, general and specialized toxicology assessments, safety pharmacology tests, genetic toxicology assays, and bioanalytical method validations.
When should IND-enabling studies begin?
Planning for IND-enabling studies should begin once a candidate molecule has been selected and sufficient preliminary data exist regarding its pharmacology, route of administration, and initial safety profile to support structured planning.
Are all IND-enabling studies GLP?
No, not all IND-enabling studies are conducted under Good Laboratory Practice conditions; GLP applicability depends on the specific study type, its intended regulatory use, and applicable statutory requirements.
How long do IND-enabling studies take?
Timelines vary widely based on the required study types, test article characteristics, dosing durations, analytical method readiness, facility scheduling, and the need for potential follow-up investigations.
How do DMPK studies support IND-enabling development?
DMPK studies characterize absorption, distribution, metabolism, and excretion to determine systemic exposure patterns, clarify clearance mechanisms, and inform safe dose selection for toxicology assessments.
What is the role of bioanalysis in IND-enabling studies?
Bioanalysis provides the validated methods needed to quantify the test article and its metabolites in biological matrices, ensuring accurate pharmacokinetic and toxicological data interpretation.
How should IND-enabling studies be sequenced?
Studies should be sequenced based on technical dependencies, ensuring that preliminary pharmacology, formulation stability, and bioanalytical methods are established before initiating definitive, resource-intensive evaluations.
Discuss Your Program with Us
Share your development goals and key challenges with our experts to define the right path forward.


